JAMA Psychiatry
March 1, 2017
Gerard Sanacora, Mark A Frye, William M. Mcdonald et al.
577 citations
IMPORTANCE: Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of...
Drugs
March 1, 2017
Marc S. Lener, Bashkim Kadriu, Carlos A. Zarate
Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as major depressive disorder and bipolar depression. In clinical studies of individuals with major depressive disorder and bipolar depression, rapid reductions in depressive symptoms have been observed in response to subanesthetic-dose ketamine, an agent whose mechanism of...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
February 28, 2017
N. Kraguljac, Matthew S. Carle, M. Frölich et al.
Retracted
Background Converging evidence from neuroimaging and post-mortem studies suggests that hippocampal subfields are differentially affected in schizophrenia. Recent studies report dentate gyrus dysfunction in chronic schizophrenia, but the underlying mechanisms remain to be elucidated. Here we sought examine if this deficit is already present in first episode psychosis, and if N-methyl-d-aspartate...
Current Neuropharmacology
February 23, 2017
Shigeyuki Chaki
40 citations
BACKGROUND: Ketamine has been reported to exert rapid and sustained antidepressant effects in patients with depression, including patients with treatment-resistant depression. However, ketamine has several drawbacks such as psychotomimetic/dissociative symptoms, abuse potential and neurotoxicity, all of which prevent its routine use in daily clinical practice. METHODS: Therefore, development of...
Behavioural Pharmacology
February 2017
Mariusz Papp, Piotr Gruca, Magdalena Lason-Tyburkiewicz et al.
Ketamine is the prototype of a new generation of antidepressant drugs, which is reported in clinical studies to be effective in treatment-resistant patients, with an effect that appears within hours and lasts for a few days. Chronic mild stress (CMS) is a well-established and widely used animal model of depression, in which anhedonia, anxiogenesis and cognitive dysfunction can be observed...
Comprehensive Psychiatry
February 2017
Verònica Gálvez, Stevan Nikolin, Kerrie-Anne Ho et al.
Animal studies suggest that neural plasticity may play a role in the antidepressant effects of a single ketamine dose. However, the potential effects of repeated ketamine treatments on human neuroplasticity are unknown. This pilot RCT study measured plasticity-induced changes before and after a ketamine course, in three treatment-resistant depressed subjects, who were randomized to receive 8...
International Journal of Molecular Sciences
January 18, 2017
Qiang Wang, Qinghui Wu, Junpeng Wang et al.
The novel synthetic psychoactive ketamine analog methoxetamine is reportedly being used for recreational purposes. As ketamine use can result in urinary dysfunction, we conducted the present study to investigate how methoxetamine affects the bladder. A cystometry investigation showed that female Sprague-Dawley rats experienced increased micturition frequency bladder dysfunction after receiving...
Journal of Affective Disorders
January 15, 2017
Steven Pennybaker, Mark J. Niciu, David A. Luckenbaugh et al.
Antidepressant response to a single subanesthetic dose infusion of the glutamatergic modulator ketamine is transient in most depressed patients; however, a minority continue to experience an extended response. This study examined depressive symptoms and potential clinical predictors of extended response to ketamine in subjects with mood disorders. Subjects were diagnosed with either major...
Forensic Sciences Research
January 2, 2017
Ricardo Dinis-Oliveira
2 citations
ABSTRACT Ketamine is a phencyclidine derivative and a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor for which glutamate is the full agonist. It produces a functional dissociation between the thalamocortical and limbic systems, a state that has been termed as dissociative anaesthesia. Considerable variability in the pharmacokinetics and pharmacodynamics between individuals...
Princeton Journal of Pre-Collegiate Research
2017
Ariel N. Shapiro, James T. McAllister, Priya V. Nair
This study investigates antidepressant onset kinetics, AMPA/NMDA ratio biomarker response prediction, and 14-day depression score durability following a single sub-anesthetic ketamine infusion in treatment-resistant major depression within the context of neuropsychopharmacology and clinical psychiatry, an area of growing scientific importance given its implications for treatment-resistant...